ChartMillAugust 6, 2026 at 4:52 PM NY29 days ago

Denali Therapeutics (NASDAQ:DNLI) Drops as Q2 AVLAYAH Revenue Misses Estimates

Denali Therapeutics (DNLI) stock fell 12% after Q2 revenue miss. AVLAYAH sales low, but Q3 guidance of $10-12M signals acceleration.

Read the Full Story at the Source

The summary here comes from the news provider; the rest of the article lives on the publisher's site — ChartMill

Companies in This Story